[Antiangiogenic treatment for neovascular glaucoma and after filtering surgery].
Bevacizumab is increasingly discussed as adjuvant treatment for rubeosis and for all stages of neovascular glaucoma. In incipient rubeosis bevacizumab has a preventive effect and arrests the progression of disease. In the case of increasing involvement of the anterior chamber angle, bevacizumab should be integrated into stage-adapted treatment to achieve successful control of intraocular pressure. The treatment of the causative ischemic stimulus is necessary in every stage of disease. One further indication for bevacizumab is the postoperative inhibition of angiogenesis after glaucoma surgery. Possible routes of administration are subconjunctival application during trabeculectomy, postoperative needling, or intravitreal injection during a filtrating operation. This review summarizes results of current studies about bevacizumab for rubeosis, neovascular glaucoma, or filtrating surgery and adds future perspectives for possible therapeutic schemes.
Eye Hospital, University Clinic of Schleswig-Holstein, University of Lübeck, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck. julia.beutel@uk-sh.de
J
J
Lüke
M
M
Lüke
S
S
Grisanti
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D018463:Filtering Surgery / Q000379:methods*; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab